INNOVATIVE ASTHMA MANAGEMENT BY COMMUNITY PHARMACISTS IN AUSTRALIA by Kritikos, Vicky
 
 
INNOVATIVE ASTHMA MANAGEMENT BY 
COMMUNITY PHARMACISTS IN AUSTRALIA 
 
 
Vicky Kritikos 
B Pharm, M Pharm (Clinical)  
 
 
A thesis submitted in fulfilment of the requirements for the 
degree of Doctor of Philosophy 
 
Faculty of Pharmacy 
 
 
 
 
March 2007
ii 
 
 
 
 
 
 
 
 
 
I wish to dedicate this thesis to my husband 
Stavros  
and my late brother 
Michael 
 
 
 
 
 
 
 
 
 
 
 
 
 
DECLARATION 
 
The research presented in this thesis was carried out under the supervision of Dr 
Sinthia Bosnic-Anticevich and Prof Carol Armour, within the Faculty of Pharmacy, 
University of Sydney. To the best of my knowledge, the work presented in this thesis 
is original, except as acknowledged in the text. Full acknowledgments have been 
made wherever the work of others has been used. This thesis has not been 
submitted in part or in whole for the award of a degree at any other University. 
 
 
 
 
 
Vicky Kritikos 
BPharm, MPharm (Clinical) 
 
 
 
 
 
 
 
 
 
 
 iii
ACKNOWLEDGEMENTS 
 
I am privileged to have been given the opportunity to do my PhD amongst 
researchers of the highest calibre in the Faculty of Pharmacy, University of Sydney. 
These people have been instrumental in supporting and assisting me throughout my 
PhD. I would like to thank the following people who have each had a special part to 
play in the completion of this thesis: 
  
Dr Sinthia Bosnic-Anticevich and Prof Carol Armour. Thank you for your kindness, 
guidance, enthusiasm, patience and the unwavering support you have given me 
during the time taken to complete my degree. It is deeply appreciated and shall never 
be forgotten. 
 
Dr Bandana Saini and Associate Prof Ines Krass. Thank you for your support and 
advice, and willingness to assist me in my hour of need on this incredible journey. 
 
Dr Tim Chen and Prof Andrew McLachlan. Thank you for your support and the 
inspiration and encouragement you have given me throughout my research. 
 
Prof Iqbal Ramzan. Thank you for your friendship and the support and assistance you 
have given me during my candidature. 
     
Dr Smita Shah and the AIM project team. Thank you for your valuable time, 
enthusiastic input and collaboration during my research. 
 
Associate Prof Ellen Sørensen and the Danish pharmacists. Thank you for your 
collaboration with Pharmacy Practice and the sharing of ideas during my research.  
 
Fran Everingham and Hui Shen Chan. Thank you for your valuable contribution, 
assistance, and support during my research.  
 
Erica Sainsbury and Dr Celina Seeto. Thank you for your sense of humour, support 
and encouragement. You are special people and I will always cherish you both. 
 
Commonwealth Department of Health and Ageing. Thank you for the funding under 
the Asthma Innovative Management Program for the AIM project in Orange, NSW. 
 
Dr Helen Watt. Thank you for the guidance and advice and the inspiration and 
encouragement you have given me over the years. You have been instrumental in 
preserving my sanity throughout my PhD. 
 iv
Bek, Michelle, Alison, Geraldine, Cassie and Simon. Thank you for your friendship, 
help and support. You have been such fantastic role models and have inspired me 
throughout my journey. You have made me feel like one of your own.  
 
Diana and Kee Chi. Thank you for your love and concern and for being there when I 
needed you most. This friendship will be treasured forever.  
 
Glena, Tipaporn, Kristy and Pradnya. Thank you for being there and for sharing all 
the ups and downs during the final stages of my PhD. 
 
The community pharmacists especially Frances Hulme, medical practitioners, high 
school staff, local media and the community in Orange, NSW. Thank you for your 
input and the overwhelming support during the AIM project. 
 
The staff at the Thoracic Society of Australia and New Zealand. Thank you for the 
assistance and continual support throughout my research. 
 
The pharmacists, respiratory physicians and participants in the studies. Thank you for 
your invaluable time, input and support with my research. 
 
The community pharmacists, Gulian, Paul, Leah, Michael, Linda, Cheryl and Jodie, 
and Dr Raj. Thank you for your understanding, input and support during my PhD.  
 
Judith Seguna and Harry Eric Abrook. Thank you for all the support, the love, the 
memories and the laughter. I will always cherish these forever. 
 
All my close family members, Aunty Ester, Millie, Paul, Afroula, Angie, Mary and all 
my good friends. Thank you for your understanding, patience and encouragement. 
 
My brother Tassie, my sister Maria and my beloved parents and brother Michael. 
Thank you for your encouragement and having such incredible faith in me. Without 
your encouragement and faith I would not have been able to complete this degree. 
 
And finally, to my pillar of support, my dearly beloved and selfless husband Stavros. 
Thank you for everything – thank you for standing by me. I could not have completed 
this thesis without your love and understanding, patience and support. 
 
 
 
Vicky 
 v
PREFACE 
 
This thesis describes research carried out between 2002 and 2005, which was based 
on the latest international [Global Initiative for Asthma (GINA) Workshop Report, 
Global Strategy of Asthma Management and Prevention] and national asthma 
management guidelines [National Asthma Council (NAC) Asthma Management 
Handbook 2002] at the time. Revised international GINA guidelines (NHLBI/WHO 
2006) and Australian asthma management guidelines (National Asthma Council 
2006) were published in 2006 during the final preparation stages of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
PUBLICATIONS AND COMMUNICATIONS 
 
Peer-reviewed journal articles 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Shah S, Taylor S, Armour C. 
Innovative asthma health promotion by rural community pharmacists: a feasibility 
study. Health Promotion Journal of Australia 2005;16(1): 69-73. 
 
Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two 
asthma knowledge questionnaires. Journal of Asthma 2005;42: 795-801. 
 
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma 
education in the community pharmacy setting: a pilot study. Journal of Asthma 
2007;44: 57-64. 
 
External conference presentations 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, 
Armour C. Innovative asthma health promotion by rural community pharmacists: a 
feasibility study.  
-podium presentation at the Australasian Pharmaceutical Science Association 
(APSA) Annual Conference 2003 (Sydney, Australia). 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Taylor S, Dalton A, Hulme 
F, Armour C. Rural community pharmacists and asthma health promotion. 
-podium presentation at the Woolcock Institute of Medical Research, Royal Prince 
Alfred Hospital. Friday Morning Research Meetings 2003 (Sydney, Australia). 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, 
Armour C. Innovative asthma health promotion by rural community pharmacists: a 
feasibility study.  
-podium presentation at the University of Sydney 4th College of Health Sciences and 
Medical Research Conference 2004 “From Cell to Society” (Leura, Australia). 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Taylor S, Dalton A, Hulme 
F, Armour C. Asthma outreach programs provided by rural community pharmacists: a 
feasibility study.  
-podium presentation at the International Primary Care Respiratory Group (IPCRG) 
2nd World Conference 2004 (Melbourne, Australia). 
 vii
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, 
Armour C. Asthma outreach programs provided by rural community pharmacists: a 
feasibility study.  
-podium presentation at the Pharmaceutical Society of Australia (PSA) NSW Young 
Pharmacists' Conference 2004 (Sydney, Australia). 
 
Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two 
asthma knowledge questionnaires. 
-poster presentation at the Australasian Pharmaceutical Science Association (APSA) 
Annual Conference 2004 (Melbourne, Australia). 
 
Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two 
asthma knowledge questionnaires. 
-poster presentation at the 13th International Social Pharmacy Workshop (ISPW) 
2004 (Malta). 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Shah S, Krass I, Dalton A, Hulme F, 
Armour C. Asthma outreach programs provided by rural community pharmacists: a 
feasibility study.  
-podium presentation by C Armour at the 13th International Social Pharmacy 
Workshop (ISPW) 2004 (Malta). 
 
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma 
education in the community pharmacy setting: a pilot study. 
-podium presentation by SZ Bosnic-Anticevich at the 14th International Social 
Pharmacy Workshop (ISPW) 2006 (Oxford). 
-podium presentation by SZ Bosnic-Anticevich at the European Respiratory Society 
16th Annual Congress 2006 (Munich). 
 
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma 
education in the community pharmacy setting: a pilot study. 
-podium presentation at the Australian Asthma Conference 2006 (Adelaide, 
Australia). 
 
 
 
 viii
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma 
education in the community pharmacy setting: a pilot study. 
-podium presentation at the University of Sydney 5th College of Health Sciences and 
Medical Research Conference 2006 “From Cell to Society” (Leura, Australia). 
 
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Innovative asthma management by 
community pharmacists in Australia. 
-podium presentation at the Woolcock Institute of Medical Research, Royal Prince 
Alfred Hospital. Friday Morning Research Meetings 2006 (Sydney, Australia). 
 
Internal faculty presentations 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative 
Management (AIM) Project. 
-podium presentation at the Faculty of Pharmacy for the AIM Steering Committee 
Meeting 2003. 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative 
Management (AIM) Project. 
-podium presentation at the Faculty of Pharmacy Postgraduate Work-in-Progress 
(2003). 
 
Kritikos V, Bosnic-Anticevich SZ, Armour C. Community pharmacists, health 
promotion and asthma. 
-podium presentation at the Faculty of Pharmacy Postgraduate Work-in-Progress 
(2004). 
 
Kritikos V, Saini B, Bosnic-Anticevich SZ, Krass I, Armour C. The Asthma Innovative 
Management (AIM) Project. 
-poster presentation at the Faculty of Pharmacy Research Day (2004). 
 
Kritikos V, Krass I, Chan HS, Bosnic-Anticevich SZ. The validity and reliability of two 
asthma knowledge questionnaires. 
-poster presentation at the Faculty of Pharmacy Research Day (2005). 
 
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Innovative asthma management by 
community pharmacists in Australia. 
-podium presentation at the Faculty of Pharmacy Seminar Series (2006). 
 ix
TABLE OF CONTENTS  
  
Declaration iii
Acknowledgements iv
Preface vi
Publications and communications vii
Table of contents x
List of tables xv
List of figures xvii
List of appendices xviii
  
CHAPTER 1: ASTHMA AND THE ROLE OF COMMUNITY PHARMACISTS 
IN ASTHMA MANAGEMENT: A REVIEW OF THE LITERATURE 
1
1.1. INTRODUCTION 1
1.2. ASTHMA 1
1.3. FACTORS INFLUENCING THE DEVELOPMENT OF ASTHMA 2
 1.3.1. Host factors 2
  1.3.1.1. Genetic predisposition 2
  1.3.1.2. Obesity 3
  1.3.1.3. Gender 3
 1.3.2. Environmental factors 3
  1.3.2.1. Allergens 3
  1.3.2.2. Infections 4
  1.3.2.3. Occupational sensitisers 4
  1.3.2.4. Tobacco smoke 4
  1.3.2.5. Outdoor/indoor air pollution 5
  1.3.2.6. Diet 5
1.4. CLASSIFICATION OF ASTHMA 5
 1.4.1. Global classification of asthma 5
 1.4.2. Australian classification of asthma 5
1.5. EPIDEMIOLOGY OF ASTHMA 6
 1.5.1. Asthma prevalence 6
 1.5.2. Asthma mortality 8
 1.5.3. Impact of asthma 9
  1.5.3.1. Impact of asthma on health care utilisation in 
Australia 
10
  1.5.3.2. Impact of asthma on quality of life in Australia 11
  1.5.3.3. Economic impact of asthma 12
 x
1.6. ASTHMA MANAGEMENT IN AUSTRALIA 14
 1.6.1. A brief history 14
 1.6.2. The role of the National Asthma Council 15
 1.6.3. The role of the State Asthma Foundations and Asthma 
Australia 
17
  1.6.3.1. The Asthma Foundations 17
  1.6.3.2. Asthma Australia 17
1.7. ASTHMA MANAGEMENT GUIDELINES 17
 1.7.1. Global asthma management guidelines 17
 1.7.2. Australian asthma management guidelines 18
 1.7.3. Evidence-based review of the Australian Asthma Management 
Plan 
22
1.8 CURRENT ISSUES IN ASTHMA MANAGEMENT 25
 1.8.1. Patient related issues 25
 1.8.2. Health care professional related issues 29
 1.8.3. Public health related issues 32
1.9. ASTHMA EDUCATION 32
 1.9.1. Effective asthma education for adults 33
  1.9.1.1. Components of the asthma education program 33
  1.9.1.2. Factors associated with the delivery of the education 37
  1.9.1.3. Setting for the education 40
1.10. EVALUATION OF THE EDUCATION 46
 1.10.1. The impact of education on asthma knowledge 46
1.11. ASTHMA AND COMMUNITY PHARMACISTS 48
 1.11.1. Community pharmacy-based asthma care programs 49
1.12. HEALTH PROMOTION AND COMMUNITY PHARMACISTS 50
 1.12.1. Community pharmacy-based health promotion activities 50
1.13. OPPORTUNITY STATEMENT 51
1.14. SCOPE AND AIMS 52
  
CHAPTER 2: ASTHMA HEALTH PROMOTION AND THE ROLE OF THE 
PHARMACIST 
53
2.1. INTRODUCTION 53
2.2. OBJECTIVES 54
2.3. METHODS 54
 2.3.1. Study design 54
 2.3.2. Recruitment of pharmacists 55
 2.3.3. Recruitment of high schools 55
 xi
 2.3.4. Adolescent health promotion 57
  2.3.4.1. Training of pharmacists 57
   2.3.4.1.1. Evaluation of training 58
  2.3.4.2. Delivery of Triple A program 58
   2.3.4.2.1. Evaluation by students 58
   2.3.4.2.2. Evaluation by pharmacists 58
   2.3.4.2.3. Evaluation by school staff 58
  2.3.4.3. Media promotion 58
 2.3.5. Community based health promotion 60
  2.3.5.1. Pharmacist training workshop 60
   2.3.5.1.1. Evaluation of the training 60
  2.3.5.2. Public forum 60
   2.3.5.2.1. Evaluation by attendees 61
  2.3.5.3. Media promotion 61
 2.3.6. Data collection from pharmacies 61
  2.3.6.1. Data collection form 61
  2.3.6.2. Semi-structured interviews with pharmacists 61
  2.3.6.3. Dispensary records of asthma medications 62
 2.3.7. Steering committee 62
 2.3.8. Establishment of local support network 62
2.4. DATA ANALYSIS 62
 2.4.1. Quantitative data 62
 2.4.2. Semi-structured interviews 63
2.5. RESULTS 65
 2.5.1. Evaluation of adolescent health promotion 65
  2.5.1.1. Evaluation of Triple A training by pharmacists 65
  2.5.1.2. Evaluation of Triple A delivery 66
   2.5.1.2.1. Evaluation of Triple A by Year 11 
students and pharmacists 
66
   2.5.1.2.2. Evaluation of Triple A by high school 
staff 
67
 2.5.2. Evaluation of community based health promotion 68
  2.5.2.1. Evaluation of workshop by pharmacists 68
  2.5.2.2. Evaluation of public forum 69
 2.5.3. Impact of health promotion activities 70
  2.5.3.1. Semi-structured interviews 70
  2.5.3.2. Triangulation of data at baseline 72
  2.5.3.3. Quantitative data from pharmacies 72
 xii
2.6. DISCUSSION 74
 2.6.1. Future directions 79
2.7. CONCLUSIONS 79
     
CHAPTER 3: THE DEVELOPMENT AND EVALUATION OF TWO ASTHMA 
KNOWLEDGE QUESTIONNAIRES 
81
3.1. INTRODUCTION 81
3.2. OBJECTIVES 82
3.3. METHODS 83
 3.3.1. Development of the questionnaires 83
 3.3.2. Reliability and validity 84
 3.3.3. Pilot testing of the questionnaires 85
  3.3.3.1. Study subjects for the pilot study 86
 3.3.4. Main study 86
  3.3.4.1. Study subjects for the main study 86
3.4. DATA ANALYSIS 86
 3.4.1. Content and face validity 86
  3.4.1.1. Readability of the instruments 87
 3.4.2. Construct validity 87
 3.4.3. Criteria-related validity 87
  3.4.3.1. Discriminant analysis 88
 3.4.4. Reliability 88
  3.4.4.1. Internal consistency 88
3.5. RESULTS 88
 3.5.1. Pilot study 88
  3.5.1.1. Sample size 89
 3.5.2. Main study 89
  3.5.2.1. Validity 90
   3.5.2.1.1. Content and face validity 90
   3.5.2.1.2. Construct validity 90
   3.5.2.1.3. Criteria-related validity 92
  3.5.2.2. Reliability 95
   3.5.2.2.1. Internal consistency 95
3.6. DISCUSSION 95
 3.6.1. Future directions 99
3.7. CONCLUSIONS 100
  
 xiii
CHAPTER 4: INTERACTIVE SMALL-GROUP ASTHMA EDUCATION IN 
THE COMMUNITY PHARMACY SETTING: A PILOT STUDY 
101 
4.1. INTRODUCTION 101 
4.2. OBJECTIVES 102 
4.3. METHODS 102 
 4.3.1. Study design 102 
 4.3.2. Recruitment of pharmacists 104 
 4.3.3. Recruitment of subjects 104 
 4.3.4. Sample size 105 
 4.3.5. Program development 105 
 4.3.6. Training of pharmacists 108 
 4.3.7. Evaluation by pharmacists 108 
4.4. DATA ANALYSIS 109 
4.5. RESULTS 109 
 4.5.1. Study sample 109 
 4.5.2. Participation and response rates 110 
 4.5.3. Baseline characteristics 110 
 4.5.4. Impact of education 112 
  4.5.4.1. Asthma knowledge 112 
  4.5.4.2. Inhaler technique 113 
   4.5.4.2.1. Optimal metered dose inhaler (MDI) 
technique 
113 
   4.5.4.2.2. Optimal dry powder inhaler (DPI) 
technique 
114 
  4.5.4.3. Asthma severity/control 115 
  4.5.4.4. Asthma-related quality of life 118 
  4.5.4.5. Medication adherence 119 
  4.5.4.6. Other asthma-related variables 120 
  4.5.4.7. Participant satisfaction 120 
 4.5.5. Evaluation by pharmacists 120 
4.6. DISCUSSION 121 
4.7. CONCLUSIONS 127 
      
CHAPTER 5: SUMMARY AND CONCLUSIONS 128 
5.1. SUMMARY 128 
5.2. CONCLUSIONS 134 
      
References 135 
Appendices A1
 xiv
LIST OF TABLES 
Table 1.1. Classification of asthma severity based on NAC guidelines 6
Table 1.2. Maintenance medications for adults 20
Table 1.3. Dose titration for maintenance therapy 21
Table 1.4. Systematic review of the six-step asthma management plan 24
Table 1.5. Summary characteristics of the 12 trials included in the Cochrane 
systematic review (Gibson et al 1998a) 
35
   
Table 1.6. Summary characteristics of the 36 trials included in the Cochrane 
systematic review (Gibson et al 1999) 
36
   
Table 1.7.  Characteristics of small-group asthma education intervention for 
adults 
39
   
Table 1.8. Effects of adult asthma self-management education interventions 
conducted in primary care 
41
   
Table 1.9. Characteristics of published asthma knowledge questionnaires 47
Table 2.1. Program strategy 64
Table 2.2. Proportion of total students in a particular year that were trained 65
Table 2.3. Evaluation of the Triple A training by pharmacists and Year 11 
students 
67
   
Table 2.4. Pharmacist evaluation of the workshops and resources 68
Table 2.5. Pharmacist evaluation of the training workshop 69
Table 2.6. Rating of public forum activities by attendees 70
Table 2.7. Perceptions of the public forum by attendees 70
Table 2.8. Asthma-related activity at baseline and post health promotion 
activities 
73
   
Table 3.1. Comparison of mean total score obtained on the CQ for people 
without asthma, people with asthma and fourth year pharmacy 
students. Maximum possible score is 14 (n = 129) 
89
   
Table 3.2. Comparison of mean total score obtained on the HQ for people 
without asthma, people with asthma and fourth year pharmacy 
students. Maximum possible score is 20 (n = 129) 
89
   
Table 3.3. Principal component estimates of the direct oblimin factor 
loadings for the 12-item CQ (n = 505) 
91
   
Table 3.4. Principal component estimates of the direct oblimin factor 
loadings for the 18-item CQ (n = 505) 
92
   
Table 3.5. Comparison of mean total score obtained on the CQ for people 
without asthma, people with asthma, pharmacists and respiratory 
physicians. Maximum possible score is 12 (n = 505) 
93
   
Table 3.6. Comparison of responses to individual items of the CQ completed 
by people without asthma, people with asthma, pharmacists, 
respiratory physicians. Number (%) of subjects responding 
correctly 
93
 xv
Table 3.7. Comparison of mean total score obtained on the HQ for people 
without asthma, people with asthma, pharmacists and respiratory 
physicians. Maximum possible score is 18 (n = 505) 
94
   
Table 3.8. Comparison of responses to individual items of the HQ completed 
by people without asthma, people with asthma, pharmacists, 
respiratory physicians. Number (%) of subjects responding 
correctly 
94
   
Table 4.1. Demographic indicators for areas selected 110
Table 4.2. Baseline characteristics of the three groups 111
Table 4.3. MARS, quality of life, asthma knowledge and optimal inhaler 
technique at baseline 
112
   
Table 4.4. Total asthma quality of life (AQOL) scores for the three groups 119
Table 4.5. MARS scores for the three groups 119
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi
 xvii 
LIST OF FIGURES 
Figure 2.1. Study design 56
Figure 2.2. The three-step process 57
Figure 2.3. Project and promotional activities timeline 59
Figure 2.4. Mean asthma knowledge scores of Year 11 students in each high 
school pre and post Triple A training 
66
   
Figure 2.5. Asthma-related pharmacy visits at four different time points 74
Figure 3.1. Study design 83
Figure 4.1. Study design 103
Figure 4.2. Steps in health promotion program planning and evaluation 106
Figure 4.3. Median asthma knowledge (interquartile range) scores for Group 
A (pharmacist-led), Group B (asthma educator-led) and Group C 
(usual care) at baseline (pre), immediately after education (post), 
and at 6 weeks (Visit 2) and 12 weeks (Visit 3) follow up 
113
   
Figure 4.4. The proportion (%) of subjects demonstrating optimal MDI 
technique in Group A (pharmacist-led), Group B (asthma 
educator-led) and Group C (usual care) at baseline (pre), 
immediately after education (post), and at 6 weeks (Visit 2) and 
12 weeks (Visit 3) follow up 
114
   
Figure 4.5. The proportion (%) of subjects demonstrating optimal DPI 
technique in Group A (pharmacist-led), Group B (asthma 
educator-led) and Group C (usual care) at baseline (pre), 
immediately after education (post), and at 6 weeks (Visit 2) and 
12 weeks (Visit 3) follow up 
115
   
Figure 4.6. The proportion (%) of subjects in each asthma severity/control 
category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 
3) follow up for Group A (pharmacist-led) (n=16) 
116
   
Figure 4.7. The proportion (%) of subjects in each asthma severity/control 
category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 
3) follow up for Group B (asthma educator-led) (n=16) 
117
   
Figure 4.8. The proportion (%) of subjects in each asthma severity/control 
category at baseline, and at 6 weeks (Visit 2) and 12 weeks (Visit 
3) follow up for Group C (usual care) (n=16) 
118
 
 
 LIST OF APPENDICES  
Appendix 1 Ethics approval for strategy 1 A1
Appendix 2 Pharmacist information and consent form A2
Appendix 3 Letters to high schools A4
Appendix 4 Triple A educators training workshop A8
Appendix 5 Asthma knowledge questionnaire A9
Appendix 6 Student information and consent form A12
Appendix 7 Asthma peer leaders’ evaluation questionnaire A14
Appendix 8 Triple A educators’ evaluation questionnaire A15
Appendix 9 Teachers’ feedback A17
Appendix 10 Local newspaper articles A18
Appendix 11 Pharmacists’ second training workshop A20
Appendix 12 Pharmacists’ workshop program A21
Appendix 13 Pharmacists’ evaluation of the second training workshop A22
Appendix 14 Exit survey for the public forum A24
Appendix 15 Media promotion of the public forum A26
Appendix 16 Data collection form for asthma-related pharmacy visits A32
Appendix 17 Objectives for semi-structured interviews A33
Appendix 18 Pilot 23-item CQ A34
Appendix 19 Pilot 41-item HQ A36
Appendix 20 Ethics approval for pilot study A39
Appendix 21 Ethics approval for main study A40
Appendix 22 The 14-item CQ A42
Appendix 23 The 20-item HQ A43
Appendix 24 The 12-item CQ A45
Appendix 25 The 18-item HQ A46
Appendix 26 Ethics approval for strategy 2 A48
Appendix 27 Participant information and consent Group A A50
Appendix 28 Program guidelines A52
Appendix 29 Baseline data collection A59
Appendix 30 Post education data collection A69
Appendix 31 Data collection at Visit 2 A71
Appendix 32 Patient satisfaction questionnaire A79
Appendix 33 Data collection at Visit 3 A82
Appendix 34 Workshop training program A90
Appendix 35 Facilitators’ guide for workshop A91
Appendix 36 Pharmacists’ evaluation A95
 
xviii 
